Last reviewed 2026-06-10 · How we verify

Diagnosis of congenital and acquired renal abnormalities — Treatment Landscape & Competitive Intelligence

Diagnosis of congenital and acquired renal abnormalities (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Diagnosis of congenital and acquired renal abnormalities, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Curium · 1 drug in Diagnosis of congenital and acquired renal abnormalities

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diagnosis of congenital and acquired renal abnormalities:

• Diagnosis of congenital and acquired renal abnormalities treatment updates — RSS
• Diagnosis of congenital and acquired renal abnormalities treatment updates — Atom
• Diagnosis of congenital and acquired renal abnormalities treatment updates — JSON

Cite this brief

Drug Landscape (2026). Diagnosis of congenital and acquired renal abnormalities — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diagnosis-of-congenital-and-acquired-renal-abnormalities. Accessed 2026-06-10.

Related

• Diagnosis of congenital and acquired renal abnormalities full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing